Mersana Therapeutics receives FDA Fast Track designation for XMT-1660 targeting advanced breast cancer, now named Emi-Le.
Quiver AI Summary
Mersana Therapeutics, Inc. announced that the FDA has granted an additional Fast Track designation for its drug XMT-1660, also known as emiltatug ledadotin (Emi-Le), aimed at treating advanced or metastatic breast cancer in patients with low or negative HER2 expression who have previously received a topoisomerase-1 inhibitor ADC. This designation follows a prior Fast Track status for treatment of recurrent triple-negative breast cancer. Mersana's CEO emphasized the challenges in treating this patient population, highlighting their commitment to advancing Emi-Le's development. The announcement accompanies plans for a conference call to discuss initial clinical trial data. Mersana focuses on developing antibody-drug conjugates for high unmet medical needs in cancer treatment.
Potential Positives
- The FDA granted an additional Fast Track designation to XMT-1660, which may expedite its development and review process for the treatment of advanced or metastatic breast cancer in a difficult-to-treat patient population.
- The World Health Organization approved emiltatug ledadotin (Emi-Le) as XMT-1660’s international nonproprietary name (INN), enhancing its marketability and recognition globally.
- This designation aligns with Mersana's focus on areas of high unmet medical need, showcasing their commitment to addressing challenging cancer treatments.
- Mersana plans to discuss initial clinical data from its Phase 1 clinical trial of Emi-Le, indicating progress in their development pipeline and transparency with investors.
Potential Negatives
- The press release highlights that the development of Mersana's drug candidates, including Emi-Le, is still in early clinical trials, indicating uncertainty regarding their effectiveness and approval timelines.
- There is a significant risk mentioned that the Fast Track designation may not expedite the development or regulatory review process as intended, raising concerns about potential delays in bringing the drug to market.
- The forward-looking statements include various risks associated with research and development, which could lead to a disparity between projected and actual outcomes, potentially impacting investor confidence.
FAQ
What is the recent FDA designation granted to Mersana Therapeutics?
The FDA granted an additional Fast Track designation to XMT-1660 for advanced or metastatic breast cancer treatment.
What is emiltatug ledadotin's international nonproprietary name?
The World Health Organization has approved emiltatug ledadotin as the international nonproprietary name for XMT-1660.
What types of breast cancer does XMT-1660 target?
XMT-1660 targets advanced or metastatic breast cancer with HER2 low or HER2-negative disease, including triple-negative breast cancer.
What benefits does Fast Track designation provide?
Fast Track designation can expedite FDA review, allowing for more frequent communication and potential Accelerated Approval or Priority Review.
How can I access Mersana's conference call?
The conference call can be accessed by dialing 833-255-2826 (domestic) or 412-317-0689 (international) at 8:30 a.m. ET.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MRSN Insider Trading Activity
$MRSN insiders have traded $MRSN stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $MRSN stock by insiders over the last 6 months:
- MOHAN BALA (SVP, Chief Development Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 15,571 shares.
- BRIAN DESCHUYTNER (SVP, COO & CFO) has traded it 2 times. They made 0 purchases and 2 sales, selling 13,687 shares.
- ALEJANDRA CARVAJAL (SVP, Chief Legal Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 13,687 shares.
- ASHISH MANDELIA (VP, Chief Accounting Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 8,216 shares.
- TIMOTHY B LOWINGER (SVP, Chief Sci.&Tech. Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 13,687 shares.
- MARTIN H. JR. HUBER (President, CEO) sold 50,423 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MRSN Hedge Fund Activity
We have seen 48 institutional investors add shares of $MRSN stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CORMORANT ASSET MANAGEMENT, LP removed 2,600,000 shares (-100.0%) from their portfolio in Q3 2024
- NEXTECH INVEST LTD. added 2,541,100 shares (+26.7%) to their portfolio in Q3 2024
- BOXER CAPITAL, LLC added 1,817,000 shares (+inf%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 1,667,956 shares (+60.8%) to their portfolio in Q3 2024
- VERITION FUND MANAGEMENT LLC added 1,292,200 shares (+11695.2%) to their portfolio in Q3 2024
- EXOME ASSET MANAGEMENT LLC added 1,178,570 shares (+inf%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP removed 1,033,759 shares (-70.5%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660. The company also announced that the World Health Organization has approved emiltatug ledadotin (abbreviated as Emi-Le) as XMT-1660’s international nonproprietary name (INN).
The new Fast Track designation is for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC), who have received a prior topoisomerase-1 inhibitor ADC. Additionally, hormone-receptor positive patients should also have received or be ineligible for endocrine therapy. The FDA previously granted Fast Track designation to Emi-Le for the treatment of adult patients with advanced or metastatic recurrent TNBC.
“Topoisomerase-1 inhibitor ADCs are rapidly becoming the standard of care for metastatic TNBC and hormone-receptor positive breast cancer, and an increasing amount of research shows that these patients are exceedingly difficult to treat thereafter,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics. “This growing population is a primary focus for us as we advance the development of Emi-Le. We are excited to announce this additional Fast Track designation and the initial clinical data from our ongoing Phase 1 clinical trial that were press released separately this morning.”
The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need. A product candidate granted Fast Track designation may be eligible for several benefits, including more frequent meetings and communications with the FDA and, if certain criteria are met, the potential for Accelerated Approval, Priority Review or Rolling Review of a Biologics License Application (BLA) by the FDA.
Conference Call Information
Mersana will host a conference call today at 8:30 a.m. ET to discuss the initial clinical data from its Phase 1 clinical trial of Emi-Le. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast that includes the data presentation will be available on the Investors & Media section of the Mersana website at
www.mersana.com
, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at
www.mersana.com
.
Forward-Looking Statements
This press release contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, those concerning Mersana’s areas of focus; the continued development and therapeutic potential of Mersana’s product candidates, including Emi-Le (XMT-1660); Mersana’s anticipated disclosure of initial clinical trial data from its Phase 1 clinical trial of Emi-Le; and the potential advantages of Fast Track Designation. Mersana may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including, among other things, uncertainties inherent in research and development and clinical development of Mersana’s product candidates, including Emi-Le; whether the outcomes of preclinical studies will be predictive of clinical trial results; the risk that the receipt of Fast Track designation for Emi-Le may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures the risk that the FDA may later decide that Emi-Le no longer meets the conditions for Fast Track designation or decide that the time period for FDA review or approval will not be shortened; the risk that Mersana may not realize the intended benefits of its platforms, technology and collaborations; and other important factors, any of which could cause Mersana’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the section entitled “Risk Factors” in Mersana’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 13, 2024, as well as in other filings Mersana may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mersana expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
